Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients - 07/08/11
, Emmanuella Guenova, MD a, Stephan Clasen, MD b, Thomas Eigentler, MD a, Andrea Forschner, MD a, Ulrike Leiter, MD a, Christina Zielinski, MD a, Björn Knaudt, MD a, Claus Garbe, MD a, Mark Berneburg, MD a
Reprint requests: Friedegund Meier, MD, Division of Dermatologic Oncology, Department of Dermatology, University of Tuebingen, Liebermeisterstr. 25, D-72076 Tübingen, Germany.Abstract |
Melanoma is highly resistant to chemotherapy. In melanoma, the PI3K-AKT-mTOR signaling pathway is constitutively activated through multiple mechanisms. Several experimental studies suggest that targeting the PI3K-AKT-mTOR signaling pathway is a promising strategy to overcome chemoresistance. This is the first report describing a chemosensitizing effect of mTOR inhibition in patients with melanoma. We report two cases of patients with metastatic melanoma who showed significant remission after combination of carboplatin and paclitaxel with the mTOR inhibitor sirolimus. Our case report, together with the literature discussed, suggests that mTOR inhibition possibly enhances the sensitivity of melanoma cells to chemotherapy and should prompt in-depth and clinical investigation.
Le texte complet de cet article est disponible en PDF.Plan
| Supported by Deutsche Forschungsgemeinschaft SFB 773. |
|
| Conflicts of interest: None declared. |
Vol 60 - N° 5
P. 863-868 - mai 2009 Retour au numéro
Article précédent
- Lip plumper contact urticaria
- Elnaz F. Firoz, Joshua M. Levin, Rachael D. Hartman, William D. James
- Transient myeloproliferative disorder with vesiculopustular eruption: Early smear is useful for quick diagnosis
- Hisashi Uhara, Masaaki Shiohara, Atsushi Baba, Junko Shiohara, Toshiaki Saida
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?